Form 4: Acrivon Therapeutics Executives Report Share Transactions for Tax Obligations

Acrivon Therapeutics' CEO and EVP reported the withholding of shares to cover tax obligations related to vesting restricted stock units.

Summary

• Acrivon Therapeutics' CEO, Peter Blume-Jensen, and EVP, Kristina Masson, reported transactions involving the company's common stock.
• These transactions occurred on November 14, 2024, and involved the withholding of shares to cover tax obligations.
• Peter Blume-Jensen had 59,766 shares withheld at a price of $7.92 per share, resulting in a remaining direct holding of 2,362,747 shares.
• Kristina Masson had 490 shares withheld at a price of $7.92 per share, resulting in a remaining indirect holding of 316,756 shares.
• The shares withheld were to satisfy mandatory tax withholding requirements upon the vesting of restricted stock units.
• Both executives disclaim beneficial ownership of the shares held by their spouse, except to the extent of their pecuniary interest.

Sentiment

Score: 7

Explanation: The document reflects routine transactions related to executive compensation and tax obligations, which is neutral to slightly positive as it indicates the executives are receiving their compensation.

Industry Context

This is a routine filing related to executive compensation and tax obligations, common in publicly traded companies.

Comparison to Industry Standards

• The share withholding for tax purposes is a standard practice for companies that offer equity-based compensation.
• Many biotech companies use restricted stock units as part of their compensation packages, and similar tax withholding transactions are common.
• Comparable companies such as Xometry, Inc. and Twist Bioscience Corporation also regularly report similar transactions by their executives.

Stakeholder Impact

• The transactions have a minimal impact on shareholders as they are related to tax obligations and do not represent a change in the company's fundamentals.

Key Dates

Keywords

Acrivon Therapeutics, Peter Blume-Jensen, Kristina Masson, share transactions, tax withholding, restricted stock units, Form 4, insider trading